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A number of metabolites of 17b-estradiol were tested for their estrogenic activity using the ER-CA-
LUX assay based on the increased expression of luciferase in exposed T47D breast cancer cells. E2b
and estrone showed similar potencies in the test, whereas E2a was 100 times less active. Incubation of
cells with estrone (0.35 mM) resulted in the formation of E2b, whereas the reverse reaction was ob-
served for E2b. The resulting equilibrium may explain the similar estrogenic potency of estrone in the
test. The synthetic 17-hydroxy benzoate ester of E2b was 3 times less active than the parent compound.
The 17-hydroxy palmitate and oleate esters of E2b, were respectively 25 and 200 times less active than
the parent compound. The 2-hydroxy metabolites of E2b and estrone showed a 5,000 to 10,000 fold
lower activity. The 4-hydroxy metabolites were more potent than the 2-hydroxy metabolites, showing
only a 20–200 times lower activity. The 2- and 4-methoxyesters of estrone were 700 times less active.
It is concluded that the estrogenic potency of metabolites formed in cattle after treatment with E2b,
like estrone, E2a and especially the esters of E2b, may be significant with respect to the potential risk
of the use of estradiol for growth promotion in domestic animals in certain countries.
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The use of 17b-estradiol for growth-promoting
purposes in cattle may result in the increased
formation of residues of not only the parent
compound but also its metabolites. In order to
investigate the potential risk for the consumer,
it is essential to obtain information on the
identity, levels and biological properties of these
compounds. In cattle the major metabolites of
E2b are estrone, the 17a-congener and their glu-
curonide conjugates (1–3). Previous studies
showed increased levels of the parent com-
pound, and the two major bovine metabolites,
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17a-estradiol and estrone, in various tissues of
implanted steers (2–4). In addition, a number of
fatty acid esters have been identified which are
very lipophilic and may as such accumulate in
the tissues (4, 5). In humans, E2b and estrone
have been shown to be partly metabolized to
their 2- and 4-hydroxy metabolites, which may
be further metabolized to their methoxy-esters.
Thus far the possible presence of these catechols
and methoxy-esters in tissues of heifers or steers
has not been investigated.
The aim of the present study was to investi-
gate the estrogenic activity of a number of estra-
diol metabolites using the recently developed
ER-CALUX assay (6). This test is based on the
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increased expression of a luciferase reporter
gene by human T47D breast cancer cells follow-
ing exposure to estrogens. In vitro models like
the E-screen and ER-CALUX assays have been
shown to be valuable tools for investigating the
estrogenic potency of individual compounds.
The present study shows that the natural es-
ters of 17b-estradiol are potent estrogens and
suggests that these should be taken into account
as residues in meat. The estrogenic potential of
metabolites that may be present as residues may
be especially important when evaluating the po-
tential risk for those consumers with the lowest
17b-estradiol production, i.e. prepubertal boys.
The higher estrogenic potency of the 4-hydroxy
as compared to the 2-hydroxy metabolites of es-
tradiol and estrone may further contribute to
the higher carcinogenic potency of these meta-
bolites (7–10). More generally, it is shown that
the metabolic potency of the cells used in the
assay may play an important role in the relative
estrogenic potency of the test compound.
MATERIALS AND METHODS
Materials
Standards of 2-hydroxy-17b-estradiol, 4-hydroxy-
17b-estradiol, 2-hydroxy-estrone, 4-hydroxy-estrone,
2-methoxy-17b-estradiol, 4-methoxy-17b-estradiol, 2-
methoxy-estrone and 4-methoxy-estrone were pur-
chased from Steraloids (Wilton, NH), 17b-estradiol,
17a-estradiol, estrone and the 3-benzoate ester of
17b-estradiol from Sigma (St. Louis, US). The oleate
and palmitate esters of 17b-estradiol were synthesized
by Dr Paris from the Laboratoire Xe´nobiotiques of
INRA in Toulouse (France) and were shown to be
free of 17b-estradiol and estrone by GC and LC/MS
analysis. Furthermore, the identity was confirmed by
1H-NMR performed at the RIKILT. Radiolabeled
[14C]17b-estradiol was obtained from N.E.N. (spe-
c.act. 1.96 GBq/mmol). Radiolabeled estrone was
purified from an incubation of human Caco-2-cells
with 17b-estradiol. Due to their possible instability,
most compounds were freshly prepared just prior to
the experiments. However, because of the limited
amounts of palmitate and oleate esters available,
these compounds were dissolved at once and the
same preparation repeatedly used.
Estrogenicity assays
The ER-CALUX assay was carried out by the Di-
vision of Toxicology at the University of Wageningen.
Modified T47D cells, expressing luciferase in re-
sponse to exposure to estrogens, were exposed to test
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compounds for 24 h in 96-well plates, essentially as
described by Legler et al. (6). Compounds were dis-
solved in DMSO and diluted in the medium. Follow-
ing exposure, cells were lysed and the luciferase activ-
ity in the lysates was determined by flash kinetics
using a microplate luminometer.
Metabolism studies
Monolayer cultures of wild-type T47D-cells were
incubated in 6-well multiwell plates (Costar, Badhoe-
vedorp, The Netherlands) with 1 ml of medium con-
taining 0.35 mM radiolabelled estradiol or estrone for
4 and 24 h. The medium was subsequently removed
and extracted twice with 2 ml diethylether. For identi-
fication of metabolites, cells were incubated in 100
mm dishes with 7.5 ml medium containing 10 mM
unlabelled 17b-estradiol or estrone.
HPLC-analysis
Following evaporation of the diethylether, the ex-
tracts were redissolved in methanol/water 1/1 (v/v)
and analysed on an HPLC system. Metabolites were
separated on a LC-ABZ column (250¿4.6 mm ID;
Supelco), heated at 40 æC and using a 1 min 50/50
isocratic elution with water/methanol/acetic acid 900/
100/8 (eluent A) and water/methanol/acetic acid 100/
900/8 (eluent B) followed by a 15 min linear gradient
to 75% eluent B. Following UV-detection (290 nm),
the eluent was mixed with scintillation cocktail prior
to on-line radioactivity detection (LB506C, Berthold,
Germany).
GC/MS analysis
GC/MS was used to check the purity of standards,
in particular the presence or absence of 17b-estradiol
and estrone, and to confirm the identity of metabo-
lites. An absolute amount of 1 mg standard was deriv-
atized with TMCS (trimethylchlorosilane)/BSTFA
(N,O-bis(trimethylsilyl)trifluoroacetamide)/pyridine
1/10/90 (v/v) and, after evaporation to dryness, redis-
solved in 10 ml dry iso-octane. Samples were investi-
gated by GC/MS in single ion monitoring, using a
DB-1 column (30 m¿0.25 mm ID; J&W Scientific,
Rancho Cordova, USA) with a film thickness of 0.25
mm. The GC/MS system (Hewlett-Packard, Rock-
ville, USA) consisted of a Model 5890 Series II gas
chromatograph, an Engine Model 5989B mass spec-
trometer (electron-impact mode), a Model 7673-A
autoinjector and a Chemstation. Injection tempera-
ture was 280 æC, oven temperature, programmed from
130 æC (held for 2 min) to 250 æC (held for 5 min) at
18.5 æC/min, then to 300 æC at 7.5 æC/min. The source
was maintained at 250 æC, the quadrupole at 120 æC.
Estradiol was e.g. identified by its retention times and
the fragments with m/z 416, 285, 326 and 129. Detec-
tion limit was 100 pg, consistent with an impurity of
less than 0.01%. For confirmation of metabolites, the
diethylether extracts were evaporated, derivatized
and analyzed in a similar way.
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Data evaluation
Dose-response curves were fitted with the software
package SlideWrite Plus 6.00 using a one-ligand
curve-fit according to the formula: responseΩ
(max.response)¿[agonist]/(EC50pi[agonist]). Curves
were used to determine the EC50 values (dose giving
50% response). Based on the EC50 value, the estro-
genic potency expressed as the relative estradiol
equivalency factor (EEF) was calculated for each
compound as EC50X/EC50E2b.
RESULTS
The estrogenic activity of 17b-estradiol and its
metabolites was studied in a number of different
tests. Typical results of the tests are shown in
Figs. 1 to 4. The calculated relative estradiol
equivalency factors (EEF), indicative for the es-
trogenic potency, are summarized in Table 1. In
all studies, 17b-estradiol was the most potent
compound, showing EC50 values between 2 and
30 pM. However, the activity of estrone was
very similar to that of 17b-estradiol (Fig. 1) and
this was confirmed in three independant studies
(data not shown). The 17a-congener was far less
potent (150–300¿), showing an EC50 value be-
tween 300 and 1000 pM.
The four catecholestrogens were less potent
than the parent compounds. However, in all
Fig. 1. Response of 17b-estradiol (closed circles), estrone (open circles), 17a-estradiol (filled triangles) in the
ER-CALUX assay. Results are expressed in relative light units (RLUs) as the mean∫SEM (nΩ3). The response
obtained with the solvent control is subtracted. Data were fitted by 1-ligand curve fitting.
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studies the 4-hydroxy metabolites were clearly
more potent than the 2-hydroxy metabolites
(Fig. 2, Table 1). The methoxyesters of estrone
were only tested once, also showing a much
lower activity than the parent compounds (Fig.
3, Table 1). The 2 and 4-methoxy-estrone meta-
bolites were of similar potency as the corre-
sponding hydroxy metabolites. Estradiol-benzo-
ate was tested twice and showed a slightly lower
activity (2–7¿) than the parent compound. The
palmitate and oleate esters also showed a clear
estrogenic activity although to a lesser extent
than the benzoate ester.
Since even slight impurities of estradiol or es-
trone may be responsible for the observed activ-
ities, all compounds were analyzed by GC/MS.
None of the standards showed detectable levels
of estrone. However, several compounds con-
tained traces of 17b-estradiol (Table 2), whereas
the 2- and 4-methoxyesters of estradiol showed
levels of parent compound of respectively 2.2%
and 1.1%. This was clearly reflected in the rela-
tively high EEF values observed for these com-
pounds being 0.4 and 0.02 for the 2- and 4-me-
thoxy esters respectively (data not shown). For
this reason these results were omitted from the
data.
In order to investigate the metabolism of 17b-
estradiol in these type of cells, wild type T47D
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Fig. 2. Response of 17b-estradiol (closed circles), 4-hydroxy-17b-estradiol (open triangles) 4-hydroxy-17b-es-
trone (open squares), 2-hydroxy-17b-estrone (filled squares), and 2-hydroxy-17b-estradiol (filled triangles) in
the ER-CALUX assay. Results are expressed as the mean∫SEM (nΩ3). The response obtained with the solvent
control is subtracted. Data were fitted by 1-ligand curve fitting.
Fig. 3. Response of 17b-estradiol (filled circles), 4-methoxy-17b-estrone (open squares) and 2-methoxy-17b-
estrone (filled squares) in the ER-CALUX assay. Results are expressed as the mean∫SEM (nΩ3). The response
obtained with the solvent control is subtracted. Data were fitted by 1-ligand curve fitting.
cells were incubated with radiolabeled estradiol.
Treatment of media samples, taken after 4 and
24 hours, with diethylether resulted in the ex-
traction of respectively 80% and 69% of the
104
radioactivity, whereas 8% and 27% remained in
the water phase. Following washing of the cells
with PBS, another 11% and 7% were released
from the cells following a number of extractions
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Fig. 4. Response of 17b-estradiol (filled circles), the 17-hydroxy-benzoate (open squares), the 17-hydroxy-palmi-
tate (filled triangles), and the 17-hydroxy-oleate esters (open triangles) in the ER-CALUX assay. Results are
expressed as the mean∫SEM (nΩ3). The response obtained with the solvent control is subtracted. Data were
fitted by 1-ligand curve fitting.
with PBS/methanol and methanol. After 24 h of
incubation, the diethylether extracts of the me-
dia samples contained about equal amounts of
the parent compound and estrone (Table 3). In-
cubation of cells with estrone resulted in the for-
mation of a peak coeluting with 17b-estradiol
(Table 3). In this case 87% and 81% of the initial
radioactivity was recovered in the diethylether
extracts from media taken after respectively 4
and 24 h, with 3% and 15% remaining in the
water phase. The cells were shown to contain
TABLE 1. Evaluation of estradiol equivalency factors
(EEF) for the various metabolites
Compound EEF
17b-estradiol 1.0
Estrone 1.0
17a-estradiol 0.03
2-hydroxy-17b-estradiol 0.00015
4-hydroxy-17b-estradiol 0.45
2-hydroxyestrone 0.00065
4-hydroxyestrone 0.0054
2-methoxyestrone 0.0015
4-methoxyestrone 0.0014
17b-estradiolbenzoate 0.25
17b-estradiolpalmitate 0.05
17b-estradiololeate 0.01
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11% and 7% of the radioactivity. The formation
of estrone from 17bE2 and reverse was con-
firmed by GC/MS analysis of extracts from me-
dia taken from cells incubated with 10 mM of
the two compounds.
DISCUSSION
Previous studies have shown that in vitro
models, like the E-screen (11) and the ER-CA-
LUX assay (6), are very suitable systems for in-
vestigating the estrogenic properties of com-
pounds. A major advantage of mammalian
TABLE 2. Level of contamination of standards with
17b-estradiol
Compound Steraloids Level of impurity
code (%)
2-hydroxyestradiol e2470 ∞0.01
4-hydroxyestradiol e2500 0.03
2-hydroxyestrone e1130 ∞0.01
4-hydroxyestrone e1170 0.02
2-methoxyestradiol e2490 2.7
4-methoxyestradiol e2510 1.1
2-methoxyestrone e1148 ∞0.01
4-methoxyestrone e1175 0.02
No estrone was detected in these standards.
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TABLE 3. Metabolism of estradiol and estrone by
T47D cells. Cells were incubated with 1 mM of the
radiolabelled compounds for 4 and 24 h. Results ex-
pressed as the fraction (%) of total radioactivity in the
radiochromatogram
Compound Time 17b- Estrone
(h) estradiol (%)
(%)
17b-estradiol 4 80∫4 14∫2
24 59∫2 39∫1
Estrone 4 11∫1 85∫2
24 43∫3 51∫2
cells, in comparison to modified yeasts, is their
closer resemblance to the target cells in vivo, in-
cluding the possible presence of mammalian en-
zymes involved in estrogen metabolism. The
present study e.g., shows a higher estrogenic ac-
tivity (EEF of 0.25) for the benzoate ester than
observed previously in yeast (EEF 0.06;12). Es-
ters, which have recently been shown to be im-
portant estradiol metabolites in cattle (4, 5),
also showed clear estrogenic activity. As a result
it seems likely that these esters also express this
activity in consumers of meat containing these
compounds. Regarding their lipophilic nature,
such compounds may easily accumulate in the
bovine tissues, but also be readily absorbed in
the GI-tract and transported in lipid particles,
initially circumventing degradation by the liver.
Based on these considerations, it is expected
that the relative estrogenic potency in treated
animals or consumers may even be higher than
observed in the present study. This is supported
by a study of Odum et al. (12), showing very
similar estrogenic potencies for 17b-estradiol
and the 3-hydroxy-benzoate ester in the rat uter-
otrophic assay.
Two other bovine metabolites, 17a-estradiol
and in particular estrone showed a marked es-
trogenic activity. The relative potencies were
similar to the relatively potencies of 0.03 and
0.5 reported by Routhledge and Sumpter (13),
using a yeast estrogen screen based on S. cerevi-
siae transfected with a gene encoding for the hu-
man estrogen receptor a. However, the estro-
genic potency of estrone was relatively high
when compared to the activity observed in the
E-screen, a proliferation assay with human
MCF-7 breast cancer cells (11). In this prolifer-
ation assay with MCF-7 cells, estrone showed a
very low estrogenic potency (EEF of 0.01), even
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lower than the 17a-congener (EEF of 0.1).
These data were confirmed by Mäkelä et al.
(14). However, these authors also investigated
the conversion of estrone into 17b-estradiol by
both MCF-7 and T47D cells and observed a 3–
4 fold higher activity in the latter cells. This is
in line with the effects observed in the present
study, showing about equimolar concentrations
of 17b-estradiol and estrone after 24 h of in-
cubation (Table 3). It is expected that this equi-
librium may be reached even earlier at the much
lower concentrations needed to obtain an estro-
genic response. The conversion of estrone to
17b-estradiol was also reported by Feldman and
Krishnan (15) for S. cerevisiae yeast and may
explain the similarity in the effects observed be-
tween the yeast assay and the ER-CALUX-
assay.
The differences observed between the estro-
genic potencies of the 4- and 2-hydroxy metabo-
lites are of particular interest, also regarding re-
ported differences in the carcinogenic potencies
of these compounds (8–10). Recently, the higher
estrogenic potency of the 4-hydroxy metabolite
of estradiol was also reported in CD-1 mice
(10), showing an increased uterine wet weight.
Using a receptor binding assay with the human
estrogen receptor, Van Aswegen et al. (16) and
Kuiper et al. (17) also reported a higher affinity
of the 4-hydroxy metabolite of 17b-estradiol as
compared to the 2-hydroxy metabolite. Accord-
ing to Anstead et al. (18), this higher affinity
may well be explained by the difference in the
effect on the proton at the 3-hydroxy group
which is essential for the binding to the recep-
tor. However, the differences observed in the
present study are much greater and this may
again be explained by differences in the met-
abolism of the compounds. In the case of ham-
sters and rats, Li et al. (19) reported a higher
activity of the enzyme COMT (catechol O-
methyltransferase) for the 2-hydroxy metabo-
lites, resulting in a faster deactivation of these
metabolites as compared to the 4-hydroxy meta-
bolites. Metabolic conversion, possibly in com-
bination with their higher chemical stability in
the culture medium, may also underly the rela-
tively high estrogenic activity of the two me-
thoxy-esters. Using a receptor binding assay the
methoxy esters of 2-and 4-hydroxy estradiol
showed very poor activity as compared to the
hydroxy metabolites (16).
ER-CALUX ASSAY ON ESTRADIOL METABOLITES
It is concluded that the natural esters should
be taken into account when evaluating the total
amount of estrogens present in meat, and in
particular their increased levels in estradiol
treated animals. The rather important meta-
bolic capacity of the test organisms has pre-
viously been pointed out by Odum et al. (12).
Although well known in the case of the esterase
activity of the organisms used for in vitro estro-
genicity screening, other possible differences in
metabolizing enzymes may also contribute sig-
nificantly to the relative potencies of specific
compounds and should be taken into consider-
ation.
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